









Markets
/
Stocks
/
nasdaq-femy
/

Femasys Inc

FEMY

0.350USD

-0.010-2.72%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

11.40MMarket Cap

LossP/E TTM



Femasys Inc

0.350

-0.010-2.72%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite strong stock market performance and technicals, the fundamentals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

118 / 207

Overall Ranking

273 / 4720

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

6.250

Target Price

+1637.08%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Femasys Inc. is a biomedical company. The Company is focused on addressing unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. The Company also developed a technology platform, namely FemEMB for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 35.06% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.63M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 65.14.

Overvalued

The company’s latest PE is -0.41, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 8.74M shares, increasing 6.37% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 951.87K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.15.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 5.41, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 409.27K, representing a year-over-year increase of 84.78%, while its net profit experienced a year-over-year increase of 2.11%.

Score

Industry at a Glance

Previous score

5.41

Change



Financials

5.38

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.54

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.77

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.30

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.09

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Healthcare Equipment & Supplies industry's average of 3.59. Its current P/E ratio is -0.42, which is 145.45% below the recent high of -1.03 and -228.82% above the recent low of -1.38.

Score

Industry at a Glance

Previous score

2.80

Change

1.2

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 118/207

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Femasys Inc is 7.00, with a high of 8.00 and a low of 3.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

6.250

Target Price

+1685.71%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

118

Total

Median

Average

Company name

Ratings

Analysts

Femasys Inc

FEMY

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Zimmer Biomet Holdings Inc

ZBH

Dexcom Inc

DXCM

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.41, which is lower than the Healthcare Equipment & Supplies industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 0.57 and the support level at 0.23, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.41

Change

-0.1

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.029

Neutral

RSI(14)

28.105

Sell

STOCH(KDJ)(9,3,3)

8.339

Oversold

ATR(14)

0.041

Low Volatility

CCI(14)

-103.258

Sell

Williams %R

97.778

Oversold

TRIX(12,20)

-2.688

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.361

Sell

MA10

0.368

Sell

MA20

0.386

Sell

MA50

0.653

Sell

MA100

0.817

Sell

MA200

1.044

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 26.88%, representing a quarter-over-quarter increase of 8.82%. The largest institutional shareholder is The Vanguard, holding a total of 951.87K shares, representing 2.21% of shares outstanding, with 37.40% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Chernett (Jorey)

1.62M

Dauntless Investment Group, LLC

1.58M

+10.16%

Uzialko (Edward R Jr.)

1.22M

The Vanguard Group, Inc.

Star Investors

825.67K

Lee-Sepsick (Kathy)

384.31K

+9.80%

Clear Creek Financial Management, LLC

270.37K

+5.46%

Geode Capital Management, L.L.C.

245.51K

+13.57%

CM Management, LLC

425.00K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.02, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is -2.64. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.